Video

Dr. Brufsky Discusses Bevacizumab Benefits in TNBC

Dr. Adam Brufsky from University of Pittsburgh School of Medicine, Discusses Bevacizumab Benefits in TNBC

Adam Brufsky, MD, PhD, professor of medicine, associate chief of hematology-oncology, and co-director of the Comprehensive Breast Center at the University of Pittsburgh School of Medicine, discusses the benefits of second-line bevacizumab (Avastin) when added to standard chemotherapy in metastatic triple-negative breast cancer (TNBC) patients.

The RIBBON-2 trial examined 684 HER2-negative locally advanced or metastatic TNBC patients. These patients were given bevacizumab in addition to the physician's choice of a second-line chemotherapy.

The median progression-free survival for the bevacizumab arm of the trial was 6.0 months compared to 2.7 months for patients on chemotherapy alone. The reduction in risk was 51% with an objective response rate of 41% for those receiving bevacizumab.

Related Videos
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Marc-Oliver Grimm, MD
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD